Global Prescription Hormonal Drugs in Gynecology Market

Prescription Hormonal Drugs in Gynecology Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024 Transparency Market Research Reports incorporated a definite business overview and investigation inclines on "Prescription Hormonal Drugs in Gynecology Market". This report likewise incorporates more illumination about fundamental review of the business including definitions, requisitions and worldwide business sector industry structure.

Hormonal imbalance in women is caused due to abnormalities in the secretion of estrogen, progesterone and as well as androgens.

A wide array of symptoms might be experienced by patients depending on the type of abnormality such as hot flushes, depression, vaginal dryness, excessive hair growth and abnormal vaginal bleeding.

Environmental and genetic factors have an influence on women's fertility through their effect on hormonal function.

Similarly, dysfunction of the HPO (hypothalamic-pituitaryovarian) axis and/or other endocrine systems may cause infertility and other gynecological disorders. The correct clinical decision for treating these diseases can be made on pathogenetic basis.

Disturbances related to the menstrual cycle lead to various syndromes such as polycystic ovary syndrome (PCOS), amenorrhea and premenstrual syndrome (PMS). Of all the above, PCOS is a common hormonal disorder seen among women that in the reproductive age.

PCOS is a condition in which appearance of the ovaries in most, but not all women, is enlarged and features a number of tiny cysts located along the outer edge of each ovary. PCOS symptoms are observed in nearly 5% to 10% of women who are in their reproductive age (typically between 12 to 45 years).

Browse Full Research Report on Prescription Hormonal Drugs in Gynecology Market: http://www.transparencymarketresearch.com/prescriptionhormonal-drugs-gynecology-market.html PCOS is perceived to be among the leading causes of female sub-fertility. It is also among the most frequently reported endocrine problems in women in the reproductive age.

Amenorrhea is a clinical condition wherein menstrual periods do not occur. Besides phases such as childhood, breastfeeding, pregnancy, and menopause, the absence of periods may point toward a problem in the female reproductive system.

However, hormonal disruption is also a common cause for the absence of menstrual periods. Similarly, PMS is a medical condition that affects many women with childbearing age and causes variety of physical and psychological symptoms that occur just before menstrual cycle.

The prevalence of hormonal imbalance rate in women is high as the World Health Organization (WHO) estimates that PCOS affected 116 million women worldwide as of 2010 i.e. nearly 3.4% of the global female population. While in case of PMS, according to World Health Organization (WHO), in 2010, 199 million women had premenstrual syndrome i.e. nearly 5.8% of the global female population.

The major drivers of the hormonal drugs in gynecology market includes high awareness in female population regarding hormonal disorders, continuous research and development activities in the field of women healthcare and various government and organizational programs to educate women about the symptoms, precautions and treatments.

The market for hormonal drugs in gynecology can be segmented on the basis of different drugs available in the market, different disease conditions and geography. Various drugs available for the treatment of hormonal disorders includes Depo-Provera, Prometrium, Provera, Alesse, Apri, Desogen, Junel Fe 1/20,

Kariva, Loestrin Fe1/20, Vestura and others. Geographic segment of prescription hormonal drugs in gynecology market can be categorized into following regions: North America, Europe, Asia-Pacific and Rest of the World.

Brisdelle (low-dose paroxetine mesylate) product of Noven Pharmaceutical received approval in July 2013 against treatment of menopause condition. Brisdelle is a low-dose formulation of paroxetine mesylate, a selective serotonin reuptake inhibitor.

Similarly, the new entity AZD4901 (Oral) is currently under phase II clinical trial for treatment of PCOS and this study is sponsored by Astra Zeneca. It is an interventional type of study including 56 as the target sample size.

The major players of prescription hormonal drugs in gynecology market includes Novartis AG, Pfizer, Inc., Berlex Laboratories, Inc., Ferring Pharmaceuticals, S.A., Duramed Pharmaceuticals, Inc. Xanodyne Pharmaceuticals, Inc., Bayer AG and others.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research

methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

About Us Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact Us Transparency Market Research State Tower, 90 State Street, Suite 700, Albany NY - 12207 United States USA - Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com